Diabetic Kidney Disease – Stumbling blocks, Discoveries and Opportunities in the 21st century
Main Article Content
Abstract
-
Downloads
Article Details
References
Ministry of Health Malaysia. National Health & Morbidity Survey 2019: Non-Communicable Diseases, Healthcare Demand and Healthcare Literacy. Available on http://iptk.moh.gov.my/images/technical_report/2020/4_Infographic_Booklet_NHMS_2019_-_English.pdf. Last accessed 25th December 2021
Hooi LS, Ong LM, Ahmad G, Bavanandan S, Ahmad NA, Naidu BM, Mohamud WN, Yusoff MF. A population-based study measuring the prevalence of chronic kidney disease among adults in West Malaysia. Kidney international. 2013 Nov 1;84(5):1034-40.
Saminathan TA, Hooi LS, Mohd Yusoff MF, Ong LM, Bavanandan S, Rodzlan Hasani WS, Tan EZ, Wong I, Rifin HM, Robert TG, Ismail H. Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study. BMC nephrology. 2020 Dec;21(1):1-1.
26th Report of the Malaysian Dialysis and Transplant Registry 2018.Kuala Lumpur 2018, ISSN 1675–8862. Available on https://www.msn.org.my/nrr/mdtr2018.jsp. Last accessed 25th Dec 2021.
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. diabetes. 2006 Jun 1;55(6):1832-9.
Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, De Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes care. 2010 Jul 1;33(7):1536-43.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology. 2017 Dec 7;12(12):2032-45.
Control TD, Group CD. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney International. 1995 Jun 1;47(6):1703-20.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet. 1998 Sep 12;352(9131):837-53.
Wei L, Xiao Y, Li L, Xiong X, Han Y, Zhu X, Sun L. The susceptibility genes in diabetic nephropathy. Kidney Diseases. 2018;4(4):226-37.
Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. New England Journal of Medicine. 1996 Jan 4;334(1):13-8.
Lim CT, Nordin NZ, Fadhlina NZ, Anim MS, Kalaiselvam T, Haikal WZ, et al. Rapid decline of renal function in patients with type 2 diabetes with heavy proteinuria: a report of three cases. BMC nephrology. 2019 Dec;20(1):1-6.
Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, Rossing P, Groop PH, Cooper ME. Diabetic kidney disease. Nature reviews Disease primers. 2015 Jul 30;1(1):1-20.
Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney international. 2006 Jun 1;69(11):2057-63.
Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. Journal of the National Medical Association. 2002 Aug;94(8 Suppl):7S.
Correlation of histopathological findings in diabetic kidney disease patients patients with rapid decline of kidney function. Mohammad Zulkarnain Bidin, Anim Md Shah, J Stanslas, Fauzah Abd Ghani, BakLeong Goh, Christopher Thiam Seong Lim. Journal of Clinical and Translational Nephrology. 2021.July; 2 (Suppl): S34.
Bidin MZ, Shah AM, Stanslas J, Seong CL. Blood and urine biomarkers in chronic kidney disease: An update. Clinica Chimica Acta. 2019 Aug 1;495:239-50.
Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease. Diabetologia. 2016 Aug;59(8):1624-7.
Danielle P. A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Altrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy with Atrasentan NCTO1858532. Available at: ClinicalTrials. gov. Accessed April. 2017;28.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New England Journal of Medicine. 2021 Aug 28.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine. 2019 Jun 13;380(24):2295-306.
Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020 Oct 8;383(15):1436-46.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The lancet Diabetes & endocrinology. 2019 Oct 1;7(10):776-85.
Tuttle KR, Rayner B, Lakshmanan MC, Kwan AY, Konig M, Shurzinske L, et al. Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis. Kidney360. 2021 Feb 25;2(2):254-62.
Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021 Feb 10.